Preclinical Imaging Market Size, Share & Industry Analysis By Modality (Optical Imaging {Bioluminescence Imaging, Fluorescence Imaging, and Others}, Nuclear Imaging {Positron Emission Tomography (PET), & Vascular Research, and Others), By End-user (Pharmaceutical & Biotechnology Companies, Academic & Research Institutes, Contract Research Organizations (CROs), and Others), and Regional Forecast, 2026-2034

The global preclinical imaging market is experiencing significant growth, primarily driven by the transition from anatomical to molecular and functional imaging, such as the PET, SPECT, optical, and multimodal systems. This allows for non-invasive tracking of cellular and molecular events in preclinical research.

Additionally, the integration of PET/CT, PET/MRI, and optical/NIR systems supports precise studies of drug efficacy and disease mechanisms, which is also anticipated to drive market growth.

Preclinical Imaging Market Driver

Rising Preclinical R&D Expenditure to Fuel Market Growth

Over the past few years, the increasing investment in pharmaceutical and biotechnology R&D has significantly driven the adoption of preclinical imaging systems. Moreover, the imaging enables visualization of drug-target interactions, biodistribution, and disease progression in animal models. This is decreasing the development time and costs. Such a scenario is anticipated to drive market expansion in the years to come.

• For instance, according to data published by the U.S. Congressional Budget Office (CBO) in April 2021, the highest estimate, valued at USD 2.30 billion (based on a 2016 study and adjusted to 2019 dollars), comprises approximately USD 0.90 billion for preclinical research and USD 1.40 billion for clinical trial expenses.

Download Free sample to learn more about this report.

According to data published by Gov.UK, in January 2024, the number of life sciences companies operating in the U.K. has been rising steadily since data collection began in 2008-09, reaching 6,850 companies in 2021-22. These companies collectively operated 7,910 sites across the U.K. in 2021-22, which marked a 1.0% increase from the previous year.

Preclinical Imaging Market Restraint

High Cost of Equipment and Maintenance to Hamper Market Growth

The preclinical imaging systems are highly expensive, depending on the modality. Additionally, the maintenance, calibration, and software updates are further adding to operational costs, limiting adoption in smaller institutions. Moreover, multimodal hybrid systems (PET/MRI, PET/CT) require specialized infrastructure and skilled technicians, which raises barriers to entry, hampering market growth.

Preclinical Imaging Market Opportunity

Integration of AI and Image Analytics to Offer Lucrative Opportunities

In recent years, artificial intelligence (AI) and deep learning have revolutionized image reconstruction and quantification in preclinical research. The AI-driven tools have significantly reduced analysis time and enhanced precision, improving reproducibility and drug evaluation outcomes. As a result, key players are integrating AI modules into imaging software to provide automated data interpretation and predictive modeling, thereby offering lucrative opportunities for market growth.

• In September 2025, Revvity launched Living Image Synergy AI. This advanced software platform integrates AI to streamline and unify preclinical imaging analysis across multiple modalities, thereby enhancing reproducibility and accelerating the drug discovery process.

Segmentation

Key Insights

The report covers the following key insights:

• Number of Preclinical Studies, By Key Countries/Region, 2024
• Technological Advancements in Preclinical Imaging
• Key Industry Developments - (Mergers, Acquisitions & Partnerships, and Others)

Analysis by Modality

Based on modality, the market is divided into optical imaging {bioluminescence imaging, fluorescence imaging, and others}, nuclear imaging {Positron Emission Tomography (PET), Single Photon Emission Computed Tomography (SPECT), and Others}, Magnetic Resonance Imaging (MRI), Computed Tomography (CT), ultrasound imaging, and others.

The optical imaging segment is expected to account for the largest market share during the forecast period. The growth is attributed to the high sensitivity, cost-effectiveness, and suitability for molecular and gene expression studies in small animals. Moreover, the increasing use of optical imaging in oncology and infectious disease models is driving its demand in preclinical research.

Analysis by Application

The market, by application, has been segmented as drug discovery & development, oncology research, neurology, cardiology & vascular research, and others.

The drug discovery & development segment is expected to hold a major share during the forecast period. The growth is driven by an increasing demand for non-invasive visualization of pharmacokinetics, biodistribution, and efficacy during early-stage drug testing in preclinical trials, which is expected to drive the adoption of preclinical imaging modalities.

Analysis by End-user

By end-user, the market is categorized into pharmaceutical & biotechnology companies, academic & research institutes, Contract Research Organizations (CROs), and others.

The pharmaceutical & biotechnology companies segment is expected to hold the largest market share in 2024. The segment growth is attributed to the large number of pharmaceutical & biotechnology companies worldwide, which are highly integrating imaging platforms to shorten preclinical timelines.

• For instance

Regional Analysis

Request for Customization   to gain extensive market insights.

The market, in terms of region, has been classified as North America, Europe, Latin America, Asia Pacific, and the Middle East & Africa.

North America held the largest share of the global preclinical imaging market in 2024. The growth is attributed to the high R&D expenditure, strong presence of pharmaceutical & biotechnology companies, and advanced research infrastructure. Moreover, the region has numerous dedicated preclinical imaging facilities within NIH-funded and university research centers. Additionally, significant investments in oncology and neuroscience research are projected to further drive product demand.

Europe held the second-largest share in 2024. The region’s growth is primarily driven by the presence of established imaging equipment manufacturers and a robust infrastructure. Additionally, the growth is supported by EU-funded initiatives, such as Horizon Europe and Euro-BioImaging, which promote the development of imaging technology and research collaboration.

• For instance, as of November 2025, the Euro-BioImaging research infrastructure in Finland connects approximately 247 imaging facilities across Europe, providing access to preclinical CT, MRI, PET, and optical imaging platforms.

Key Players Covered

Major players, including Bruker, Mediso Ltd., and Revvity, dominate the global preclinical imaging market. These players are launching new products to support clinical research worldwide, which is contributing to their significant market share globally.

The report includes the profiles of the following key players:

• Bruker (U.S.)
• Mediso Ltd. (Hungary)
• Revvity (U.S.)
• FUJIFILM Corporation (Japan)
• MILabs B.V. (Netherlands)
• Siemens Healthineers AG (Germany)
• MR Solutions (U.K.)
• Miltenyi Biotec (Germany)
• Trifoil Imaging LLC (U.S.)
• Aspect Imaging Ltd. (Israel)

Key Industry Developments

• June 2025: FUJIFILM Corporation launched the Vevo F2 LAZR-X20, a multi-modal photoacoustic imaging platform featuring advanced laser technology for high-resolution, real-time tissue characterization in preclinical research.
• September 2023: Revvity unveiled several next-generation preclinical imaging technologies, including the IVIS Spectrum 2 and IVIS SpectrumCT 2 systems, Quantum GX3 microCT imaging solution, and the Vega ultrasound system, to enhance high-throughput and sensitive in vivo imaging for accelerated scientific discoveries and drug development.